Peak Bio
Clinical-stage bio-pharmaceutical company focused on innovative therapeutics that address significant unmet medical need for patients with inflammatory, rare and specialty diseases, and cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 15 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (1682 %) | (1955 %) | - |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (1570 %) | (2154 %) | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
| R&D % of revenue | 1348 % | 646 % | - |
Source: Company filings or news article
Related Content
Peak Bio is a biotechnology company based in the San Francisco Bay Area, specializing in the development of small molecules, antibodies, and antibody-drug conjugates (ADCs). The company targets the healthcare sector, focusing on creating best-in-class therapeutics to address unmet medical needs. Peak Bio's lead product candidate, PHP 303, is a 5th generation, phase 2 clinical-ready neutrophil elastase inhibitor, aimed at treating conditions related to inflammation and immune response. The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. Peak Bio operates in the competitive biotechnology market, leveraging its experienced management team with over 50 years of industry expertise. The business model revolves around advancing its clinical pipeline, acquiring new targeted assets, and developing innovative oncology treatments through its internal platform. Revenue is generated through product development, clinical trials, partnerships, and potential future sales of approved therapeutics.
Keywords: biotechnology, small molecules, antibodies, ADCs, therapeutics, clinical trials, inflammation, immune response, oncology, healthcare, innovation.